BioTime, Inc. (NYSEMKT:BTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “

Other equities research analysts also recently issued reports about the stock. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $6.50 price target (up from $6.00) on shares of BioTime in a research report on Monday, June 19th. ValuEngine upgraded shares of BioTime from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, BidaskClub upgraded shares of BioTime from a “sell” rating to a “hold” rating in a research report on Thursday, September 28th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $5.33.

Shares of BioTime (NYSEMKT BTX) traded down 1.06% during trading on Tuesday, reaching $2.81. The company had a trading volume of 256,120 shares. The firm has a 50 day moving average price of $2.81 and a 200 day moving average price of $3.01. BioTime has a 12 month low of $2.47 and a 12 month high of $3.96. The company has a market cap of $325.41 million, a price-to-earnings ratio of 4.72 and a beta of 1.37.

ILLEGAL ACTIVITY WARNING: “BioTime, Inc. (BTX) Lifted to Hold at Zacks Investment Research” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/10/biotime-inc-btx-lifted-to-hold-at-zacks-investment-research.html.

In related news, Director Broadwood Partners, L.P. bought 10,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average price of $2.60 per share, with a total value of $26,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 173,896 shares of company stock worth $481,220 over the last three months.

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of BioTime by 15.1% in the first quarter. Vanguard Group Inc. now owns 3,146,178 shares of the biotechnology company’s stock worth $10,855,000 after purchasing an additional 413,073 shares during the last quarter. Jane Street Group LLC grew its stake in shares of BioTime by 19.4% in the first quarter. Jane Street Group LLC now owns 92,685 shares of the biotechnology company’s stock worth $320,000 after purchasing an additional 15,080 shares during the last quarter. Nationwide Fund Advisors grew its stake in shares of BioTime by 2.2% in the first quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 939 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of BioTime by 306.7% in the first quarter. Russell Investments Group Ltd. now owns 96,303 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 72,624 shares during the last quarter. Finally, Swiss National Bank grew its stake in shares of BioTime by 18.7% in the first quarter. Swiss National Bank now owns 110,586 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 17,400 shares during the last quarter.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.